GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (FRA:BM8) » Definitions » ROE % Adjusted to Book Value

Biomarin Pharmaceutical (FRA:BM8) ROE % Adjusted to Book Value : 4.11% (As of Dec. 2024)


View and export this data going back to 1999. Start your Free Trial

What is Biomarin Pharmaceutical ROE % Adjusted to Book Value?

Biomarin Pharmaceutical's ROE % for the quarter that ended in Dec. 2024 was 9.28%. Biomarin Pharmaceutical's PB Ratio for the quarter that ended in Dec. 2024 was 2.26. Biomarin Pharmaceutical's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was 4.11%.


Biomarin Pharmaceutical ROE % Adjusted to Book Value Historical Data

The historical data trend for Biomarin Pharmaceutical's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical ROE % Adjusted to Book Value Chart

Biomarin Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.01 -0.41 0.80 0.95 3.63

Biomarin Pharmaceutical Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 2.14 2.75 3.17 4.11

Competitive Comparison of Biomarin Pharmaceutical's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Biomarin Pharmaceutical's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomarin Pharmaceutical's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's ROE % Adjusted to Book Value falls into.


;
;

Biomarin Pharmaceutical ROE % Adjusted to Book Value Calculation

Biomarin Pharmaceutical's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=8.20% / 2.26
=3.63%

Biomarin Pharmaceutical's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=9.28% / 2.26
=4.11%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomarin Pharmaceutical ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical Business Description

Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.

Biomarin Pharmaceutical Headlines

No Headlines